Quinidine syncope. A report of successful treatment with bretylium tosylate.
Quinidine syncope is an unpredictable side effect of quinidine administrateion which has a mortality rate of 11.5 per cent when managed with conventional drugs and direct-current countershock. In 2 patients with quindine syncope, the arrhythmias were effectively controlled within 30 minutes following the slow infusion of 150 mg. of bretylium tosylate. This control is contrasted with 2 cases managed in the conventional manner. Bretylium tosylate is a quaternary amine with unique antifibrillatory properties and appears to have a significant role in the management of these arrhylmias.
D000328:Adult; D001281:Atrial Fibrillation / Q000188:drug therapy; D001949:Bretylium Compounds / Q000627:therapeutic use*; D001950:Bretylium Tosylate / Q000627:therapeutic use*; D004562:Electrocardiography; D005260:Female; D006801:Humans; D008875:Middle Aged; D011802:Quinidine / Q000009:adverse effects* / Q000627:therapeutic use; D013575:Syncope / Q000139:chemically induced / Q000188:drug therapy*; D013610:Tachycardia / Q000139:chemically induced / Q000188:drug therapy*
D001949:Bretylium Compounds; D001950:Bretylium Tosylate; D011802:Quinidine